Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan
Koichiro Akakura, Hiroji Uemura, Satoru Kawakami, Akira Yokomizo, Motonobu Nakamura, Kazuo Nishimura, Tetsushi Komori, Dianne Athene Ledesma, Koichiro Akakura, Hiroji Uemura, Satoru Kawakami, Akira Yokomizo, Motonobu Nakamura, Kazuo Nishimura, Tetsushi Komori, Dianne Athene Ledesma
Abstract
Aim: We aimed to determine Japanese metastatic castration resistant prostate cancer (CRPC) patients' Ra-223 treatment experience. Patients & methods: Patients answered the Cancer Therapy Satisfaction Questionnaire (CTSQ domains: Satisfaction with Therapy [SWT], Expectations of Therapy [ET], Feelings about Side Effects [FSE]), the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) and the FACT-Bone Pain (FACT-BP) Questionnaire at baseline, during (Visits 3 and 5) and after treatment (end of observation; EOO). Results: Data from 72 patients were included. Baseline median CTSQ scores SWT: 66.1 (IQR19.7), ET: 75.0 (IQR45), and FSE 68.8 (IQR 34.4) were unchanged during Visits 3 and 5, but the SWT (-3.57 [IQR17.9]) and ET (-5.0 [IQR30]) decreased while FSE was unchanged (0.0 [IQR31.25]) at EOO. The median MAX-PC (18.0 [IQR 49]) score was unchanged (0.0, IQR 6) while the median FACT BP (54.0 [IQR13]) score decreased by -1.0 (IQR 8) at EOO. Conclusion: Japanese metastatic castration resistant prostate cancer patients' experience is stable during Ra-223 treatment.
Keywords: HRQoL; Ra-223; anxiety; mCRPC; prostate cancer; treatment satisfaction.
Source: PubMed